CSL urges biotech immunity from policy see-saws
SYDNEY: Australian biotech giant CSL’s chief scientific officer, Andrew Cuthbertson, has warned a future Labor government against changing incentives that support local medical research.
Professor Cuthbertson said his plea to any future government was to not tweak programs the biotech sector relied on, as a transition to new projects could take years and cause damage.
“Continuity and the ability to make long-term plans — given our R&D projects often run for a decade or more — is very important to us,” he said.
“If the incentives or rules keep changing then it makes it hard for us to make those long-term investment plans.”
A federal election is expected in May next year and on current polling Bill Shorten is expected to lead Labor to victory, ousting the Morrison government.
Professor Cuthbertson said when there was a change of government there was often a year-long review of schemes and changes made.
“That creates a lot of down time and can cause harm to academic scientists trying to do translation work and small biotechs because they could run out of money while governments are changing gears and changing the system,” he said.
The scientific expert added that while Australia had already had a debate on the corporate tax rate and the research and development tax incentive, any future debate should not be an internal examination of Australia but understanding its globally competitive position.
“We have to be competitive with other countries, like Singapore, Switzerland, the UK and others, who absolutely want medical research and medical research translation and drug development to occur in their country,” Professor Cuthbertson said.
The CSL executive added that while any future tweaks to the R&D tax incentive was not the most important aspect the company assessed when deciding to develop a project in Australia, it did affect long-term strategic thinking.
“Altering the R&D tax incentive won’t make us start or stop an individual project but in our long-term planning on where we invest, build our facilities and hire people, it absolutely affects those strategic decisions,” he said.
Professor Cuthbertson was speaking yesterday after the company held its annual research and development briefing for about 100 analysts in Sydney.
The company revealed “real world” data that showed its cell-based influenza vaccine proved move effective than its traditional egg-based product during the US flu season.
The Australian-listed company outlined that the real-world data was based on an analysis of 1,353,862 medical records. CSL said analysing real-world data from electronic medical records was a new approach to understanding the effectiveness of influenza vaccines.
Digital medical records have been in the spotlight in Australia following the rollout of the My Health Record, which has seen people opting out because of data security concerns.
Professor Cuthbertson said it was important that the benefits of a My Health Record to not only individuals, but society, was clearly explained to the population.
“If we have a system that is high quality and protects people’s privacy but allows us to look at anonymised data, you would have to believe that there will be multiple societal benefits of that across Australia,” he said.
“That benefit would be in terms of understanding disease incidence and the effectiveness of treatment,” Professor Cuthbertson said.
“You need a lot of people to use it because the more people who opt out, the less powerful it is as a tool.”






